FindTrial
Sign In

A phase II study, multicenter, open label trial of R1415 (erlotinib hydrochloride) in patients with advanced/metastatic or recurrent non-small cell lung cancer. (JO18396)

A phase II study, multicenter, open label trial of R1415 (erlotinib hydrochloride) in patients with advanced/metastatic or recurrent non-small cell lung cancer. (JO18396)

Status
Unknown
Phases
Phase 2
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080220075
Enrollment
Unknown
Registered
2005-09-09
Start date
2005-09-09
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced or metastatic or recurrent non-small cell lung cancer

Interventions

investigational material(s) Generic name etc : erlotinib hydrochloride INN of investigational material : Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investiga

Sponsors

Chugai Pharmaceutical Co., Ltd.
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients with advanced/metastatic or recurrent NSCLC (stage IIIB or IV) who have failed at least one previous chemotherapy regimen.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Efficacy and safety—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026